19th May 2025 19:54
AstraZeneca PLC - Cambridge-based pharmaceutical and biotechnology company - Phase 3b Batura trial shows statistically significant and clinically meaningful improvements in mild asthma in patients treated with Airsupra (albuterol and budesonide) than albuterol alone. Compared to placebo, Airsupra significantly reduces the risk of a severe symptom exacerbation by 47%. Patients treated with airsupra have 63% lower exposure to total systemic corticosteroids over the treatment period compared with albuterol-alone, reducing risks from cumulative exposure to SCS which include type 2 diabetes, depression and anxiety, renal impairment, cataracts, cardiovascular disease, pneumonia and fractures.
Craig LaForce, medical director of North Carolina Clinical Research says: "The unprecedented Batura trial results provide an opportunity to change 50 years of clinical practice in asthma. For decades, millions of patients have relied on albuterol-only rescue treatment in asthma, leaving them unprotected against the increasing airway inflammation that could lead to a more serious attack. The results from the Airsupra Batura trial add to a wide body of evidence on the value of the anti-inflammatory reliever rescue approach to not only provide immediate relief from symptoms, but also reduce inflammation to prevent future and more severe exacerbations for patients living with asthma across all severities."
Current share price: 10,292.00p, closed down 0.4% in London on Monday
12-month change: down 15%
By Aidan Lane, Alliance News reporter
Comments and questions to [email protected]
Copyright 2025 Alliance News Ltd. All Rights Reserved.
Related Shares:
Astrazeneca